G-Protein-coupled estrogen receptor (GPER)-specific agonist G-1 reduces cell proliferation in gastrointestinal cancer cells independently of GPER1 receptor presence
DOI:
https://doi.org/10.56782/pps.743Keywords:
AGS cells, colon cancer, estrogen receptors, gastric cancer, HT-29 cellsAbstract
Cancer is considered the second leading cause of death worldwide, following cardiovascular diseases. It is believed that the effect of estrogen is not only limited to tumors of hormonally regulated tissues such as the breast, endometrium, and ovary, but also plays a role in the development of gastric and colorectal cancer. Therefore, this study aimed to investigate the apoptotic and antiproliferative effects of G-Protein-Coupled Estrogen Receptor (GPER)-Specific Agonist G-1 on gastrointestinal adenocarcinoma cells. G-1 was applied to human gastric cancer (AGS) and human colon cancer (HT-29) cells at different concentrations. Real-time cellular analysis (RTCA) and MTT assay were used to evaluate cell proliferation. Flow cytometry was employed for the detection of early and late apoptosis using the Annexin-V FITC Kit, Hoechst staining, and analysis of Caspase-3 activation. siRNA was used to knockdown GPER1 expression at the transcriptional level. G-1 exhibited concentration- and time-dependent antiproliferative effects on AGS and HT-29 cells. At the highest concentration, G-1 induced apoptosis in both cell lines. G-1 showed similar antiproliferative effects on cells with and without siRNA treatment. The data suggest that the antiproliferative effects of G-1 appeared to be independent of GPER1 activation G-1 appears to be an attractive tool for suggesting novel targets in the treatment of gastric and colorectal adenocarcinomas.
Downloads
References
1. World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. WHO; 2020. Accessed December 11, 2020.
2. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R. L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2022, 74(3), 229-263. DOI: 10.3322/caac.21834. DOI: https://doi.org/10.3322/caac.21834
3. Flegiel, E.; Piotrowska, M.; Ptasznik, M.; Baran, A.; Lenart, J.; Podrażka, M.; Mazurek, J.; Stachowicz, H.; Bartos, W.; Adamczyk, M. Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer. Prospect. Pharm. Sci. 2024, 22(4), 7–15. DOI: 10.56782/pps.229 DOI: https://doi.org/10.56782/pps.229
4. Wang, S.; Zheng, R.; Li, J.; Zeng, H.; Li, L.; Chen, R.; Sun, K.; Han, B.; Bray, F.; Wei, W.; He, J. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol. Hepatol. 2024, 9, 229–37. DOI: 10.1016/S2468-1253(23)00366-7 DOI: https://doi.org/10.1016/S2468-1253(23)00366-7
5. Armstrong, C.M.; Autumn, R.B.; Allred, K.F.; Sturino, J. M.; Weeks, B.R.; Allred, C.D. A novelshift in estrogen receptor expression occurs as estradiols uppresses inflammation-associated colon tumor formation. Endocrine-Related Cancer. 2013, 20, 515–525. DOI: 10.1530/ERC-12-0308 DOI: https://doi.org/10.1530/ERC-12-0308
6. Prentice, R.L.; Pettinger, M.; Beresford, S.A.; Wactawski-Wende, J.; Hubbell, F.A.; Stefanick, M.L.; Chlebowski, R.T. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol. Biomarkers Prev. 2009, 18(5), 1531–1537. DOI: 10.1158/1055-9965.EPI-08-1209 DOI: https://doi.org/10.1158/1055-9965.EPI-08-1209
7. Yuk, J.S.; Yang, S.W.; Yoon, S.H.; Kim, M.H.; Seo, Y.S.; Lee, Y.; Kim, J.; Yang, K.; Gwak, K.; Cho, H. The increased risk of colorectal cancerin the women who underwent hysterectomyfrom the South Korean National HealthInsurance Database. BMC Women’s Health. 2023, 23(1), Art. No: 519. DOI: 10.1186/s12905-023-02642-3 DOI: https://doi.org/10.1186/s12905-023-02642-3
8. Henderson, B.E.; Feigelson, H.S. Hormonal carcinogenesis. Carcinogenesis 2000, 21(3), 427-433. DOI: 10.1093/carcin/21.3.427 DOI: https://doi.org/10.1093/carcin/21.3.427
9. Fisher, C.S.; Wachtel, M.S.; Margenthaler, J.A. Outcomes for patients who develop both breast and colorectal cancer. Ann. Surg. Oncol. 2012, 19, 242–248. DOI: 10.1245/s10434-011-1843-8 DOI: https://doi.org/10.1245/s10434-011-1843-8
10. Di Leo, A.; Messa, C.; Russo, F.; Misciagna, G.; Guerra, V.; Taveri, R.; Leo, S. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa, Preliminary results. Dig. Dis. Sci. 1994, 39(9), 2038-2042. DOI: 10.1007/BF02088144 DOI: https://doi.org/10.1007/BF02088144
11. Klaassen, C.D., Watkins, J.B., Casarett, L.J. Casarett&Doull’s Essentials of Toxicology, 2nd ed.; McGraw-HillMedical, New York, 2010.
12. Filardo, E.J.; Thomas, P. Minireview G protein-coupled estrogen receptor-1, GPER1-1: Its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 2012, 153, 2953–2962. DOI: 10.1210/en.2012-1061 DOI: https://doi.org/10.1210/en.2012-1061
13. Sanden, C.; Broselid, S.; Cornmark, L.; Andersson, K.; Daszkiewicz-Nilsson, J.; Mårtensson, U.E.; Olde, B.; Leeb-Lundberg, L.M. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol. Pharmacol. 2011, 79, 400–410. DOI: 10.1124/mol.110.069500 DOI: https://doi.org/10.1124/mol.110.069500
14. Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R. Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occursvia trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14, 1649–1660. DOI: 10.1210/mend.14.10.0532 DOI: https://doi.org/10.1210/mend.14.10.0532
15. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A trans membrane intracellular estrogen receptor mediate srapid cell signalling. Science 2005, 307, 1625–1630. DOI: 10.1126/science.1106943 DOI: https://doi.org/10.1126/science.1106943
16. Owman, C.; Blay, P.; Nilsson, C.; Lolait, S.J. Cloning of human cDNA encoding a novel hepta helix receptor expressed in Burkitt' slymphoma and widely distributed in brain and peripheral tissues. Biochem. Biophys. Res. Commun. 1996, 228, 285-292. DOI: 10.1006/bbrc.1996.1654 DOI: https://doi.org/10.1006/bbrc.1996.1654
17. Otto, C.; Fuchs, I.; Kauselmann, G.; Kern, H.; Zevnik, B.; Andreasen, P.; Schwarz, G.; Altmann, H.; Klewer, M.; Schoor, M.; Vonk, R.; Fritzemeier, K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod. 2009, 80(1), 34-41. DOI: 10.1095/biolreprod.108.071175 DOI: https://doi.org/10.1095/biolreprod.108.071175
18. Mizukami, Y. In Vivo Functions of GPR30/GPER1-1, a Membrane Receptor for Estrogen: From Discovery to Functions In Vivo. Endocrinology 2010, 2, 101-107. DOI: 10.1507/endocrj.k09e-332 DOI: https://doi.org/10.1507/endocrj.K09E-332
19. Haas, E.; Meyer, M.R.; Schurr, U.; Bhattacharya, I.; Minotti, R.; Nguyen, H.H.; Heigl, A.; Lachat, M.; Genoni, M.; Barton, M. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007, 49, 1358-1363. DOI: 10.1161/HYPERTENSIONAHA.107.089995 DOI: https://doi.org/10.1161/HYPERTENSIONAHA.107.089995
20. Xu, F.; Ma, J.; Wang, X.; Wang, X.; Fang, W.; Sun, J.; Li, Z.; Liu, J. The Role of G Protein-Coupled Estrogen Receptor (GPER1) in Vascular Pathology and Physiology. Biomolecules 2023, 13, Art. No: 1410. DOI: 10.3390/biom13091410 DOI: https://doi.org/10.3390/biom13091410
21. Chen, C.; Gong, X.; Yang, X.; Shang, X.; Du, Q.; Liao, Q.; Xie, R.; Chen, Y.; Xu, J. The roles of estrogen and estrogen receptors in gastrointestinal disease (Review). Oncol. Lett. 2019, 18, 5673-5680. DOI: 10.3892/ol.2019.10983 DOI: https://doi.org/10.3892/ol.2019.10983
22. Liu, Q.; Chen, Z.; Jiang, G.; Zhou, Y.; Yang, X.; Huang, H.; Liu, H.; Du, J.; Wang, H. Epigenetic down regulation of G protein-coupled estrogen receptor (GPER1) functions as a tumor suppressor in colorectal cancer. Mol. Cancer 2017, 16, Art. No: 87. DOI: 10.1186/s12943-017-0654-3 DOI: https://doi.org/10.1186/s12943-017-0654-3
23. Bologa, C. G.; Revankar, C. M.; Young, S. M.; Edwards, B. S.; Arterburn, J. B.; Kiselyov, A. S.; Prossnitz, E. R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2(4), 207–212. DOI: 10.1038/nchembio775 DOI: https://doi.org/10.1038/nchembio775
24. Prossnitz, E. R.; Barton, M. The G protein–coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 2011, 7(12), 715–726. DOI: 10.1038/rendo.2011.122 DOI: https://doi.org/10.1038/nrendo.2011.122
25. Ariazi, E. A.; Cunliffe, H. E.; Lewis-Wambi, J. S.; Slifker, M. J.; Willis, A. L.; Kimbro, K. S.; Jordan, V. C. Estrogen induces apoptosis in breast cancer cells via GPER. Cancer Res. 2010, 70(13), 6037–6048. DOI: 10.1073/pnas.1115188108 DOI: https://doi.org/10.1073/pnas.1115188108
26. Dennis, M. K.; Field, A. S.; Burai, R.; Ramesh, C.; Petrie, W. K.; Bologa, C. G.; Prossnitz, E. R. Identification of a GPER antagonist with improved estrogen receptor selectivity. Endocrinology 2009, 150(1), 284–295. DOI: 10.1016/j.jsbmb.2011.07.002 DOI: https://doi.org/10.1016/j.jsbmb.2011.07.002
27. Kurt, A.H.; Bozkus, F.; Uremis, N.; Uremis, M.M. The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells. Renal failure 2016, 38(5), 686–692. DOI: 10.3109/0886022X.2016.1155398 DOI: https://doi.org/10.3109/0886022X.2016.1155398
28. Eroglu, Z.; Erdem, C.; Oktem, G.; Bozok Cetintas, V.; Duzgun, Z. Effect of SIRT1 activators and inhibitors on CD44+/CD133+‑enriched non‑small cell lung cancer cells. Mol. Med. Rep. 2020, 22, 575-581. DOI: 10.3892/mmr.2020.11113 DOI: https://doi.org/10.3892/mmr.2020.11113
29. Kara, H. G.; Doğan, E.; Bozok, V; Aktan, C.; Cakiroglu, E.; Eroglu, Z.; Aygunes-Jafari, D.; Korkmaz, K.S.; Senturk, S.; Kosova, B. The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS Journal. 2025, 292, 3755–3770. DOI: 10.1111/febs.70099 DOI: https://doi.org/10.1111/febs.70099
30. Atay, A.; Gürdal, I.; Bozok Çetıntas, V.; Üşümez, A.; Cal, E. Effects of New Generation All-Ceramic and Provisional Materials on Fibroblast Cells. J. Prosthodont. 2019, 28, e383–e394. DOI: 10.1111/jopr.12915 DOI: https://doi.org/10.1111/jopr.12915
31. Bozok Cetintas, V.; Tezcanli Kaymaz, B.; Aktug, H.; Oltulu, H.; Taskiran, D. Capsaicin induced apoptosis and gene expression dysregulation of human acute lymphoblastic leukemia CCRF-CEM cells. JBUON 2014, 19(1), 183-190.
32. Bozok-Cetintas, V.; Tetik, A.; Cok, G.; Kucukaslan, A.S.; Kosova, B.; Gunduz, C.; Veral, A.; Eroglu Z. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells. Cell Biol. Int. 2013, 37, 78–86. DOI: 10.1002/cbin.10006 DOI: https://doi.org/10.1002/cbin.10006
33. Chan, Q.K.; Lam, H.M.; Ng, C.F.; Lee, A.Y.; Chan, E.S.; Ng, H.K.; Ho, S.M.; Lau, K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010, 17(9), 1511-1523. doi: 10.1038/cdd.2010.20 DOI: https://doi.org/10.1038/cdd.2010.20
34. Ariazi, E.A.; Brailoiu, E.; Yerrum, S.; Shupp, H.A.; Slifker, M.J.; Cunliffe, H.E.; Black, M. A.; Donato, A.L.; Arterburn, J. B.; Oprea, T.I.; Prossnitz, E.R.; Dun, N.J.; Jordan, V.C. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010, 1(70), 1184-1194. DOI: 10.1158/0008-5472.CAN-09-3068 DOI: https://doi.org/10.1158/0008-5472.CAN-09-3068
35. Kurt, A.H.; Çelik, A.; Kelleci, M.B. Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells. Oncol. Lett. 2015, 10(5), 3177–3182. DOI: 10.3892/ol.2015.3711 DOI: https://doi.org/10.3892/ol.2015.3711
36. Wang, C.; Lv, X.; He, C.; Hua, G.; Tsai, M.Y.; Davis, J. S. The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis. 2013, 4, Art. No: e869. DOI: 10.1038/cddis.2013.397 DOI: https://doi.org/10.1038/cddis.2013.397
37. Rekha, P.; Gupta, A.; Goud, K.S.; Biswas, B.; Bhattar, S.; Vijayakumar, G.; Selvaraju, S. GPER induces mitochondrial fission through p44/42 MAPK - Drp1 pathway in breast cancer cells. Biochem. Biophys. Res. Commun. 2023, 643, 16–23. DOI: 10.1016/j.bbrc.2022.12.061 DOI: https://doi.org/10.1016/j.bbrc.2022.12.061
38. Casaburi, I.; Avena, P.; De Luca, A.; Sirianni, R.; Rago, V.; Chimento, A.; Trotta, F.; Campana, C.; Rainey, W. E.; Pezzi, V. GPER-independent inhibition of adrenocortical cancer growth by G-1 involves ROS/Egr-1/BAX pathway. Oncotarget. 2017, 8(70), 115609–115619. DOI: 10.18632/oncotarget.23314 DOI: https://doi.org/10.18632/oncotarget.23314
39. Hirtz, A.; Lebourdais, N.; Rech, F.; Bailly, Y.; Vaginay, A.; Smaïl-Tabbone, M.; Dubois-Pot-Schneider, H.; Dumond, H. GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation. Cells 2021, 10(12), Art. No: 3438. DOI: 10.3390/cells10123438 DOI: https://doi.org/10.3390/cells10123438
40. Liu, X.; Yang, Y.; Tang, X.; Guo, L.; Tang, X.; Zhu, T.; Zhao, T.; Zhang, W.; Zhang, P. Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells. Evid. Based. Complement. Alternat. Med. 2022, 2022, Art. No: 6517732. DOI: 10.1155/2022/6517732 DOI: https://doi.org/10.1155/2022/6517732
41. Wei, W.; Chen, Z.J.; Zhang, K.S.; Yang, X.L.; Wu, Y.M.; Chen, X.H.; Huang, H.B.; Liu, H.L.; Cai, S.H.; Du, J.; Wang, H.S. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 2014, 2(5), Art. No: 1428. DOI: 10.1038/cddis.2014.398 DOI: https://doi.org/10.1038/cddis.2014.398
42. Lv, X.; He, C.; Huang, C.; Hua, G.; Wang, Z.; Remmenga, S.W.; Rodabough, K.J.; Karpf, A.R.; Dong, J.; Davis, J.S.; Wang, C. G-1 inhibits breast cancer cell growth via targeting colchicine-binding site of tubulin to interfere with microtubule assembly. Mo.l Cancer Ther. 2017, 16(6), 1080–1091. DOI: 10.1158/1535-7163.MCT-16-0626 DOI: https://doi.org/10.1158/1535-7163.MCT-16-0626
43. Gilligan, L.C.; Rahman, H.P.; Hewitt, A.M.; Sitch, A.J.; Gondal, A.; Arvaniti, A.; Taylor, A.E.; Read, M.L.; Morton, D. G.; Foster, P.A. Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via GPER. J. Clin. Endocrinol. Metab. 2017, 102(12), 4435–4447. DOI: 10.1210/jc.2016-3716 DOI: https://doi.org/10.1210/jc.2016-3716
44. Lee, S.J.; Kim, T.W.; Park, G.L.; Hwang, Y.S.; Cho, H.J.; Kim, J.T.; Lee, H.G. G protein-coupled estrogen receptor-1 agonist induces chemotherapeutic effect via ER stress signaling in gastric cancer. BMB Rep. 2019, 52(11), 647–652. DOI: 10.5483/BMBRep.2019.52.11.007 DOI: https://doi.org/10.5483/BMBRep.2019.52.11.007
45. Weißenborn, C.; Ignatov, T.; Ochel, H.J.; Costa, S.D.; Zenclussen, A.C.; Ignatova, Z.; Ignatov, A. GPER1 functions as a tumor suppressor in triple-negative breast cancer cells. J. Cancer Res. Clin. Oncol. 2014, 140(5), 713-23. DOI: 10.1007/s00432-014-1620-8 DOI: https://doi.org/10.1007/s00432-014-1620-8
46. Huang, Y.; Chen, S.; Lei, Y.; Chung, C.; Chan, M.; Chen, L.; Zhong, Y.; Zhang, E.; Chen, J.; Deng, L. β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway. Recent Pat. Anticancer Drug Discov. 2022, 17(3), 312-321. DOI: 10.2174/1574892817666211222150409 DOI: https://doi.org/10.2174/1574892817666211222150409
47. Zhao, X.; Li, X.; Ren, O.; Tian, J.; Chen, J. Calycosin induces apoptosis in colorectal cancer cells, through modulating the ERβ/MiR-95 and IGF-1R, PI3K/Akt signaling pathways. Gene 2016, 591(1), 123-128. DOI: 10.1016/j.gene.2016.07.012 DOI: https://doi.org/10.1016/j.gene.2016.07.012
48. Shi, D.; Li, H.; Zhang, Z.; He, Y.; Chen, M.; Sun, L.; Zhao, P. Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER1 mediated PI3K/AKT signaling pathway. PLoS ONE 2022, 17(1), Art. No: e0262389. DOI: 10.1371/journal.pone.0262389 DOI: https://doi.org/10.1371/journal.pone.0262389
49. Bustos, V.; Nolan, A.M.; Nijhuis, A.; Harvey, H.; Parker, A.; Poulsom, R.; McBryan, J.; Thomas, W.; Silver, A.; Harvey, B.J. GPER1 mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget. 2017, 8, 84258-84275. DOI: 10.18632/oncotarget.20653 DOI: https://doi.org/10.18632/oncotarget.20653
50. Hao, J.; Bao, X.; Jin, B.; Wang, X.; Mao, Z.; Li, X.; Wei, L.; Shen, D.; Wang, J.L. Ca2+ channel subunit α 1D promotes proliferation and migration of endometrial cancer cells mediated by 17β-estradiol via the G protein-coupled estrogen receptor. FASEB J. 2015, 29(7), 2681-3109. DOI: 10.1096/fj.14-265603 DOI: https://doi.org/10.1096/fj.14-265603
51. Bayer, J.; Gläscher, J.; Finsterbusch, J.; Schulte, L.H.; Sommer, T. Linear and inverted U-shaped dose-response functions describe estrogen effects on hippocampal activity in young women. Nat. Commun. 2018, 9, Art. No: 1220. DOI: 10.1038/s41467-018-03679-x DOI: https://doi.org/10.1038/s41467-018-03679-x
52. Gui, Y.; Shi, Z.; Wang, Z.Y.; Li, J.J.; Xu, C.; Tian, R.; Song, X.; Walsh, M.P.; Li, D.; Gao, J.; Zheng, X.L. The GPER agonist G-1 induces mitotic arrest and apoptosis in human vascular smooth muscle cells independent of GPER. J. Cell Physiol. 2015, 230(4), 885-895. DOI: 10.1002/jcp.24817 DOI: https://doi.org/10.1002/jcp.24817
53. Nilsson, B.O.; Olde, B.; Leeb-Lundberg, L.M. G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br. J. Pharmacol. 2001, 163(6), 1131–1139. DOI: 10.1111/j.1476-5381.2011.01235.x DOI: https://doi.org/10.1111/j.1476-5381.2011.01235.x
54. Dennis, M.K.; Burai, R.; Ramesh, C.; Petrie, W.K.; Alcon, S.N.; Nayak, T.K.; Bologa, C.G.; Leitao, A.; Brailoiu, E.; Deliu, E.; Dun, N.J.; Sklar, L.A.; Hathaway, H.J.; Arterburn, J.B.; Oprea, T.I.; Prossnitz, E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5(6), 421–427. DOI: 10.1038/nchembio.168. DOI: https://doi.org/10.1038/nchembio.168
55. Torres-López, L.; Olivas-Aguirre, M.; Villatoro-Gómez, K.; Dobrovinskaya, O. The G-Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Proliferation and Causes Apoptosis in Leukemia Cell Lines of T Lineage. Front. Cell Dev. Biol. 2022, 10, Art. No: 811479. https://doi.org/10.3389/fcell.2022.811479 DOI: https://doi.org/10.3389/fcell.2022.811479
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Akif Hakan Kurt, Vildan Bozok, Cansu Kara Oztabag, Metiner Tosun
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
